Valuation: Turn Therapeutics Inc.

Market Cap 272M 237M 219M 202M 381M 26.16B 389M 2.62B 1.03B 12.81B 1.02B 998M 44.11B P/E 2024 *
-
P/E 2025 -34.2x
Enterprise Value 267M 233M 215M 198M 374M 25.68B 382M 2.57B 1.01B 12.58B 1B 980M 43.3B EV / Sales 2024 *
-
EV / Sales 2025 -
Free-Float
45.88%
Yield 2024 *
-
Yield 2025 -
1 day+1.00%
1 week-3.39%
Current month+24.93%
1 month+51.24%
3 months+163.58%
6 months+100.00%
Current year+131.47%
1 week 8.51
Extreme 8.51
10.18
1 month 5.55
Extreme 5.554
11.69
Current year 3.01
Extreme 3.01
11.69
1 year 2.57
Extreme 2.5701
26.5
3 years 2.57
Extreme 2.5701
26.5
5 years 2.57
Extreme 2.5701
26.5
10 years 2.57
Extreme 2.5701
26.5
Manager TitleAgeSince
Chief Executive Officer 48 06/01/2015
Director of Finance/CFO 31 01/05/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 48 -
Director/Board Member 46 01/10/2018
Director/Board Member 61 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
04/06/26 Free

Director

71,666 0.2406%
04/06/26 Free

Director

95,000 0.3189%
04/06/26 Free

Director

83,334 0.2798%
Change 5-day change 1-year change 3-year change Capi.($)
+1.00%-3.39% - - 272M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.40%-2.70%+40.77%+183.80% 23.38B
Weighted average by Cap. -2.80%-2.36%+40.12%+144.11%

Financials

2024 2025
Net sales - -
Net income -1.77M -1.55M -1.43M -1.31M -2.48M -170M -2.53M -17.05M -6.7M -83.41M -6.64M -6.5M -287M -3.19M -2.79M -2.58M -2.37M -4.47M -308M -4.57M -30.79M -12.11M -151M -12M -11.73M -519M
Net Debt -752K -657K -606K -559K -1.05M -72.38M -1.08M -7.24M -2.85M -35.45M -2.82M -2.76M -122M -5M -4.37M -4.03M -3.71M -7M -481M -7.15M -48.15M -18.94M -236M -18.76M -18.35M -811M
Logo Turn Therapeutics Inc.
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
Employees
2
Date Price Change Volume
17/07/26 $9.120 +1.00% 104,610
16/07/26 $9.030 -5.74% 88,922
15/07/26 $9.580 -0.62% 97,856
14/07/26 $9.640 +1.80% 70,062
13/07/26 $9.470 +0.32% 207,859

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TTRX Stock